VANCE BRAY, MD
Rheumatology Physician · DENVER, CO
Individual Active NPI 1568456127
Medicare payment data Part B · 2024
| Year | Beneficiaries | Services | Submitted | Allowed | Paid |
|---|---|---|---|---|---|
| 2024 | 522 | 101,141 | $3,336,708 | $1,799,478 | $1,425,732 |
| 2023 | 567 | 96,585 | $3,477,391 | $1,909,430 | $1,509,924 |
| 2022 | 528 | 94,216 | $3,811,079 | $1,857,958 | $1,466,527 |
Top procedures (2024)
| HCPCS | Description | Services | Avg allowed | Avg paid |
|---|---|---|---|---|
| J3262 | Injection, tocilizumab, 1 mg | 20,960 | $6 | $5 |
| J1602 | Injection, golimumab, 1 mg, for intravenous use | 19,650 | $11 | $9 |
| J0129 | Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 10,825 | $43 | $34 |
| J0897 | Injection, denosumab, 1 mg | 10,440 | $25 | $20 |
| J3111 | Injection, romosozumab-aqqg, 1 mg | 3,990 | $11 | $9 |
| J1010 | Injection, methylprednisolone acetate, 1 mg | 3,680 | $0 | $0 |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | 3,450 | $30 | $24 |
| J9312 | Injection, rituximab, 10 mg | 2,900 | $77 | $61 |
| 99214 | Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more | 625 | $128 | $95 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 612 | $0 | $0 |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | 415 | $133 | $103 |
| J7050 | Infusion, normal saline solution, 250 cc | 401 | $1 | $1 |
Taxonomy & licensure
| Specialty | Code | Primary | License | State |
|---|---|---|---|---|
| Rheumatology Physician | 207RR0500X | ✓ | 29019 | CO |
Other Rheumatology Physician providers in Colorado
- NPI 1255728085
- NPI 1639145923
- NPI 1538780382
- NPI 1245312495
- NPI 1669436259
- NPI 1285885095
- NPI 1922521442
- NPI 1750302592
Source: NPPES (public domain) and CMS Medicare Physician & Other Practitioners data. Not affiliated with CMS, NPPES, or any government agency.